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Prostaglandin E2 (PGE2) plays an important role in immunosuppression and tumor growth. PGE2 inhibitors
such as aspirin and indomethacin suppress experimental tumor growth. Little is known of the relationship
between PGE2 synthesis in brain tumors and the dose of aspirin or indomethacin. The present study was
undertaken to evaluate the effect of different doses of aspirin and indomethacin on PGE2 synthesis in
C6 glioma cells. C6 glioma cells were incubated with different concentrations (2, 4, and 8 µM) of aspirin
and indomethacin for 1, 2, 4, 6, 8, 12, and 24 hours. Intracellular PGE2 concentration was measured by
enzyme immunoassay. Each concentration of aspirin and indomethacin effectively inhibited PGE2
synthesis. Concentrations of 2, 4, and 8 µM of aspirin significantly inhibited PGE2 production at 6, 4, and
1 hours, respectively, and the inhibition persisted for more than 24 hours (p < 0.05). Concentrations of
2 and 4 µM of indomethacin were effective at 4 and 2 hours (p < 0.05), respectively. However, inhibition
was not observed beyond 12 hours (p > 0.05). Indomethacin 8 µM was effective at 1 hour and the inhibition
persisted beyond 24 hours (p < 0.05). Our study demonstrates that aspirin and indomethacin inhibit PGE2
synthesis in C6 glioma cells and that low-dose aspirin is as effective as high-dose aspirin. This study may
encourage future clinical use of low-dose aspirin in the prevention or treatment of brain tumors.
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Malignant gliomas are the most common primary
intracranial tumors. In spite of aggressive surgery, radiation
therapy, and chemotherapy, these tumors are uniformly
fatal. Immunosuppression has been observed in patients
with brain tumors [1–3]. Glioma-mediated immuno-
suppression has been attributed to the release of soluble
factors by the tumor, including transforming growth factor
β2 [4–6] and prostaglandin E2 (PGE2) [7–9]. In a previous
report, we noted that malignant brain tumors contained a
high concentration of PGE2 and that surgical removal
reduced PGE2 production [10]. The anti-inflammatory
effects of aspirin and indomethacin are mainly due to
their ability to inhibit prostaglandin production via
cyclooxygenase (COX) [11,12]. Theoretically, inhibition of
the synthesis or release of PGE2 by tumors may
decrease immunosuppression, inhibiting tumor growth.
In experiments, growth of brain tumors is suppressed
by administration of PGE2 inhibitors such as aspirin
and indomethacin [13,14]. However, little is known of
the relationship between PGE2 synthesis in brain
tumors and dose of nonsteroidal anti-inflammatory
drug (NSAID). In this study, we evaluated the effects of
different doses of aspirin and indomethacin on PGE2
synthesis in C6 glioma cells.
MATERIALS AND METHODS
C6 glioma cells were cultured in RPMI-1640 culture medium
supplemented with 10% fetal bovine serum, 100 U/mL
Kaohsiung J Med Sci January 2004 • Vol 20 • No 1
S.L. Hwang, K.S. Lee, C.L. Lin, et al
2
penicillin, and 100 µg/mL streptomycin. Cultured
cells were maintained at 37°C in 5% CO2. Cells were
cultured in standard 96-well microtitre plates (1 × 105
cells/well) at subconfluent conditions and allowed to ad-
here overnight. They were then incubated with various
concentrations of either aspirin (2, 4, or 8 µM) or indo-
methacin (2, 4, or 8 µM) for 1, 2, 4, 6, 8, 12, or 24 hours.
Intracellular PGE2 concentrations were measured using the
BiotrakTM PGE2 competitive enzyme immunoassay kit
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). All
reactions were measured using a micro-ELISA Vmax
photometer.
Ten samples of C6 glioma cells were cultured with each
concentration of aspirin or indomethacin. Mean values and
standard errors of the mean were calculated and were
compared using Student’s t test. A p value of 0.05 or less was
considered significant.
RESULTS
Each concentration of aspirin and indomethacin effectively
inhibited PGE2 synthesis. However, both the onset and
duration of inhibition varied with concentration (Table).
With higher concentrations, the onset of PGE2 inhibition
was earlier and the duration was longer than with lower
concentrations. Concentrations of 2 and 4 µM of aspirin
inhibited PGE2 production at 6 and 4 hours, respectively,
and the inhibition persisted for more than 24 hours (p <
0.05). Concentrations of 2 and 4 µM of indomethacin were
effective at 4 and 2 hours, respectively (p < 0.05). However,
inhibition was not observed beyond 12 hours (p > 0.05). A
concentration of 8 µM of aspirin or indomethacin inhibited
PGE2 production at 1 hour and the inhibition persisted for
more than 24 hours (p < 0.05).
DISCUSSION
Tumor-induced immunosuppression is a fundamental
problem in cancer biology and immunotherapy. Increasing
evidence has demonstrated that the COX metabolite PGE2
exhibits potent immunosuppressive effects [15–17]. PGE2
has been considered an important modulator of dendritic
cell function, altering cytokine production and expression
of cell surface markers [18,19]. Recent studies show that
COX-2 and PGE2 may play important roles in tumor
angiogenesis [15,20,21]. Clinical studies in patients with
brain tumors also demonstrate broad suppression of general
host immunocompetence [1–3]. PGE2 is associated with
glioma-mediated immunosuppression [22–24]. Importantly,
the growth of brain tumors can be suppressed by the
administration of PGE2 inhibitors such as aspirin and
indomethacin [13,14].
Recent reviews have summarized the accumulating
evidence that NSAIDs may be used clinically to prevent or
treat cancer [25–27]. NSAIDs suppress malignant trans-
formation and tumor growth by stimulating apoptosis and
inhibiting angiogenesis. Numerous experimental, epide-
miologic, and clinical studies have found that long-term use of
aspirin or other NSAIDs results in a lower risk of colorectal
cancer, adenomatous polyps, and, to some extent, other tumors
such as breast, lung, esophageal, and gastric cancer [28].
Despite enthusiasm about the potential usefulness of NSAIDs
as anticancer agents, little has been reported about the effects
of aspirin or other NSAIDs on brain tumors.
Table. Alteration in intracellular prostaglandin (PG) E2 concentration (pg/µL) after treatment with aspirin or indomethacin
Drug and dose 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr
Control 62.9 ±  12.4 47.3 ±  5.8 43.3 ±  5.6 46.8 ±  6.9 52.3 ±  7.7 52.4 ±  7.5 50.4 ±  6.8
Aspirin
2 µM 53.5 ±  8.6 40.6 ±  8.5 51.5 ±  10.6 12.5 ±  2.6* 24.5 ±  3.9* 28.3 ±  4.0* 29.3 ±  3.5*
4 µM 55.4 ±  6.9 51.5 ±  8.4 33.4 ±  6.4* 21.0 ±  4.9* 19.4 ±  3.4* 22.4 ±  5.1* 30.5 ±  4.9*
8 µM 38.4 ±  3.0* 19.4 ±  3.9* 19.5 ±  3.3* 20.4 ±  4.5* 19.5 ±  5.0* 24.3 ±  5.6* 28.5 ±  3.8*
Indomethacin
2 µM 69.5 ±  15.9 52.5 ±  9.8 32.2 ±  5.6* 12.3 ±  2.4* 32.5 ±  4.0* 62.5 ±  7.3 50.3 ±  5.5
4 µM 62.4 ±  4.5 31.5 ±  5.8* 42.4 ±  7.5 9.3 ±  2.0* 23.4 ±  3.3* 58.4 ±  7.1 56.5 ±  4.1
8 µM 40.3 ±  3.2* 16.4 ±  3.4* 16.4 ±  3.2* 39.6 ±  4.1* 32.7 ±  4.4* 28.4 ±  5.2* 33.4 ±  3.4*
*Significant decrease in intracellular PGE2 concentration when compared with control, Student’s t test, p < 0.05.
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Two distinct isoforms of the COX enzyme, COX-1 and
COX-2, have been identified, and these are encoded by
different genes [29,30]. COX-1 is constitutively expressed in
most tissues and plays an important role in platelet
aggregation and gastric cytoprotection [31,32]. Although
COX-2 is expressed constitutively in the human kidney and
brain, its expression is induced rapidly in response to
growth factors, oncogenes, tumor promoters, and carcino-
gens, as well as to physiologic stress stimuli [33]. NSAIDs
vary in their ability to inhibit COX-1 or COX-2 at different
concentrations and in different tissues. Traditional NSAIDs
(such as aspirin, indomethacin, sulindac, and ibuprofen)
are non-selective and inhibit COX-1 and COX-2. Traditional
NSAIDs and selective COX-2 inhibitors (e.g. celecoxib)
inhibit chemically-induced carcinogenesis in rats and mice
[34,35]. The highest tolerated dose of non-selective NSAIDs
typically reduced the number and size of tumors by 40% to
60%, but did not completely eliminate the growth of
chemically-induced adenomatous polyps and cancers.
However, high doses of celecoxib inhibit 90% of tumors in
rats and are better tolerated than comparable doses of non-
selective NSAIDs [34,35]. COX-1 activity, perhaps through
the induction of COX-2, may also be essential in the
development of colorectal cancer [36,37]. A role for COX-1
in the induction of COX-2 might explain why, in epide-
miologic studies, aspirin use is associated with a reduced
risk of colorectal cancer even at doses and dosing intervals
that could not sustain COX-2 inhibition in nucleated cells
[38,39].
Despite enthusiasm about the potential usefulness of
NSAIDs, particularly the selective COX-2 inhibitors, as
anticancer drugs, unresolved questions about their safety,
efficacy, mechanisms of action, optimal treatment regimens,
and contraindications limit their clinical application in
chemoprevention and therapy. Aspirin prophylaxis has
become standard in the prevention of cardiovascular disease
and its balance of risks and benefits is clearer than for other
NSAIDs. Therefore, we evaluated the effectiveness of aspirin
and indomethacin on the inhibition of PGE2 synthesis in C6
glioma cells. The results showed that low-dose aspirin (2
and 4 µM) was as effective as aspirin at a higher dose (8 µM)
in inhibiting PGE2 synthesis in C6 glioma cells, although
low-dose aspirin acted later. The onset of PGE2 inhibition
with low-dose indomethacin (2 and 4 µM) was later and the
duration was shorter than with high-dose indomethacin
(8 µM). In this study, we demonstrated that aspirin and
indomethacin can inhibit PGE2 production, and that low-
dose aspirin is as effective as high-dose aspirin. Clinically,
low-dose aspirin has been widely used to prevent myo-
cardial infarction and thrombotic stroke while minimizing
gastrointestinal toxicity. This study may encourage future
clinical use of low-dose aspirin in the prevention and
treatment of brain tumors.
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